ImmuCell (NASDAQ:ICCC) Shares Cross Above Two Hundred Day Moving Average - Here's Why

Key Points

• ImmuCell crossed above its 200-day moving average of $6.11 (trading as high as $6.33) but was last at $6.05 on 44,136 shares and noted as trading down about 5.3%.
• Weiss Ratings upgraded the stock from "sell (d+)" to "hold (c-)", and MarketBeat shows the consensus analyst rating as Hold.
• In the latest quarter ImmuCell reported an EPS loss of -$0.32 on $7.63 million revenue, with negative ROE and net margin, a market cap near $54.8M, and roughly 13.5% institutional ownership.

ImmuCell Corporation (NASDAQ:ICCC - Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $6.11 and traded as high as $6.33. ImmuCell shares last traded at $6.05, with a volume of 44,136 shares trading hands.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded shares of ImmuCell from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Tuesday, February 24th. One research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the company presently has an average rating of "Hold".

ImmuCell Trading Down 5.3%

The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.76 and a current ratio of 4.21. The business's 50 day moving average price is $6.43 and its 200-day moving average price is $6.11. The firm has a market cap of $54.75 million, a price-to-earnings ratio of -55.00 and a beta of 0.27.

ImmuCell (NASDAQ:ICCC - Get Free Report) last posted its quarterly earnings results on Wednesday, March 4th. The biotechnology company reported ($0.32) EPS for the quarter. ImmuCell had a negative return on equity of 3.52% and a negative net margin of 3.76%.The firm had revenue of $7.63 million during the quarter.

Institutional Investors Weigh In On ImmuCell

A number of institutional investors have recently made changes to their positions in the company. Geode Capital Management LLC raised its position in shares of ImmuCell by 4.2% during the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company's stock valued at $500,000 after acquiring an additional 2,907 shares in the last quarter. Steadtrust LLC boosted its holdings in ImmuCell by 79.1% in the fourth quarter. Steadtrust LLC now owns 56,770 shares of the biotechnology company's stock worth $349,000 after purchasing an additional 25,070 shares during the period. Finally, Mesirow Financial Investment Management Inc. boosted its holdings in ImmuCell by 199.6% in the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company's stock worth $224,000 after purchasing an additional 24,303 shares during the period. 13.47% of the stock is currently owned by institutional investors.

About ImmuCell

ImmuCell Corporation NASDAQ: ICCC is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company's flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.